Clinical Trials in Philadelphia

Showing 4181-4200 of 15,860 trials

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

NCT05233618

In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients will receive up to about 9 cycles of treatment with Tag and have a bone marrow biopsy after cycle 4 and about 1 year after HCT.

MyelofibrosisChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia

Karen Ballen, MD44 participantsStarted Jul 2022

Philadelphia, Pennsylvania, United States • Charlottesville, Virginia, United States

COMPLETEDPhase 2< 1 mile

An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

NCT04538989

The objective of this trial is to evaluate the safety, tolerability and glucose-raising effects of RZ358 in patients with Congenital Hyperinsulinism (HI).

Congenital Hyperinsulinism

Rezolute23 participantsStarted Feb 2020

Philadelphia, Pennsylvania, United States • Fort Worth, Texas, United States • Sofia, Bulgaria +14 more locations

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

Find Trials by Condition in Philadelphia

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Hybrid Coronary Revascularization Trial

Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults

Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

A Clinical Study on Implants With TiUltra Technology and Associated Prosthetic Components

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

REGENETEN™ Bioinductive Implant System in Full-thickness Tears

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

Conduction System Pacing With INGEVITY+

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

HbA1c Variation Study

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants